Success Story: I-140 NIW Approval for an M.D. Advancing AI-Based Prediction Models for Common Diseases
Client’s Testimonial:
"Thank you for all your great guidance and service.”
On March 31st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Human Genetics (Approval Notice).
General Field: Human Genetics
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Mongolia
State of Residence at the Time of Filing: Texas
Approval Notice Date: March 31st, 2026
Processing Time: 11 months, 8 days (Premium Processing Upgrade Requested)
Case Summary:
Our firm recently secured an I-140 NIW approval for our client, an M.D. working in the field of human genetics. In the petition, we presented the client’s proposed endeavor, which focused on continuing research on advanced AI-based prediction models for common diseases, including cardiovascular and neurological conditions. This work aims at identifying key risk factors through integrated genetic, environmental, and socio-economic analysis. We showed that this work was not only scientifically strong but also positioned to inform clinical guidelines and improve population-level health outcomes.
A central part of the case was showing that the client’s endeavor had substantial merit and national importance. Rather than describing the work in overly broad terms, we framed it as a practical research agenda aimed at improving risk prediction, earlier intervention, and better health decision-making in areas that carry major public-health consequences. The petition also connected the client’s work to disease prevention and more effective clinical management, helping show why this research had significance beyond a single employer or institution.
We also demonstrated that the client was well-positioned to advance the proposed endeavor. The client had received an M.D. and was already working in the United States as a bioinformatics fellow, continuing research directly related to disease prediction, cardiometabolic traits, heart disease, and genetic risk analysis. That ongoing role helped show continuity between past achievements and future plans.
The evidentiary record further supported that conclusion. The client had authored 6 peer-reviewed journal articles, including 1 first-authored paper, along with 2 first-authored conference abstracts and 1 first-authored preprint. These metrics were persuasive not simply because of volume, but because they reflected a consistent research record in topics tied to the proposed endeavor. The client’s work had also been cited 104 times, which we used to show independent reliance by other researchers. Importantly, at least 2 of the client’s papers ranked among the top 10% most-cited articles in Clinical Medicine for their publication years, helping demonstrate that the impact of the work was measurable relative to field and time, not just raw citation totals.
Another important factor was external validation. The client’s research had received support from major funding sources, including the Millennium Challenge Corporation and the World Health Organization. We used that evidence to reinforce that respected organizations had already invested in research connected to the client’s broader scientific direction. The petition also included 2 recommendation letters that highlighted the client’s technical background, research contributions, and future promise in this area. As one expert evaluator noted:
“With a robust record of influential publications, [Client] is an invaluable asset in her field, capable of fostering impactful advancements in genetic research.”
This approval reflects the strength of a case built around a clearly defined endeavor, objective evidence of research impact, and a persuasive explanation of why the client’s work in AI-based disease prediction would benefit the United States. We are delighted to see the client’s I-140 NIW approved and look forward to their continued contributions in human genetics and public health.